XFOR
NASDAQ
US
X4 Pharmaceuticals, Inc. - Common Stock
$4.24
▼ $-0.11
(-2.53%)
Vol 206K
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$349.7M
ROE
-343.7%
Margin
-279.9%
D/E
123.44
Beta
0.49
52W
$1–$27
Wall Street Consensus
9 analysts · Apr 20264
Strong Buy
4
Buy
1
Hold
0
Sell
0
Strong Sell
88.9%
Buy Rating
Price Chart
Similar Stocks
DMAC
DiaMedica Therapeutics Inc
$414.5M
CABA
Cabaletta Bio Inc
$210.8M
XOMA
Xoma Royalty Corp
P/E 15.2
$329.3M
IRD
Opus Genetics Inc
$138.6M
NGNE
Neurogene Inc
$319.1M
FBRX
Forte Biosciences Inc
$341.6M
SRZN
Surrozen Inc
$193.7M
GLSI
Greenwich Lifesciences Inc
$291.1M
PALI
Palisade Bio Inc
$350.2M
CLYM
Climb Bio Inc
$272.7M
Earnings
Beat rate: 80.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.35 | $-0.22 | +$0.13 |
| Sep 2025 | $-0.93 | $-0.69 | +$0.24 |
| Jun 2025 | $-4.42 | $-3.47 | +$0.95 |
| Mar 2025 | $-4.53 | $0.04 | +$4.57 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -375.3% | -375.3% | -375.3% | -375.3% | -343.7% | -343.7% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -1304.7% | -311.1% | -311.1% | -311.1% | -279.9% | -279.9% |
| Gross Margin | 83.5% | 83.0% | 83.0% | 83.0% | 83.2% | 83.2% |
| D/E Ratio | 1909.87 | 1909.87 | 1909.87 | 1909.87 | 123.44 | 123.44 |
| Current Ratio | 3.19 | 3.19 | 3.19 | 3.19 | 5.65 | 5.65 |
Key Ratios
ROA (TTM)
-69.8%
P/S (TTM)
10.29
P/B
5.6
EPS (TTM)
$-10.50
CF/Share
$-0.72
Rev Growth 3Y
-5.2%
52W High
$26.83
52W Low
$1.35
$1.35
52-Week Range
$26.83
How does XFOR compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
XFOR valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
10.3
▼
20%
below
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
5.7
▲
130%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
XFOR profitability vs Biotechnology peers
ROE
-343.7%
▼
411%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
-279.9%
▲
2%
above
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
83.2%
▲
6%
above
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-69.8%
▼
49%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
XFOR financial health vs Biotechnology peers
D/E ratio
123.4
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
5.7
▲
27%
above
peers
(4.4)
vs Peers
vs Industry
Below avg
Beta
0.5
▼
50%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
XFOR fundamentals radar
XFOR
Peer median
Industry
XFOR profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio